Form 4: Incyte Executive Michael Morrissey Acquires Shares Through Performance-Based Award

EVP Michael Morrissey acquired 4,649 shares of Incyte common stock on April 1, 2025, based on the achievement of performance criteria, with vesting contingent on continued service.

Summary

• Michael James Morrissey, EVP, Head of Tech. Operations at Incyte Corp, acquired 4,649 shares of common stock on April 1, 2025, as part of a performance-based award.
• These shares were earned based on the achievement of specific Opzelura performance goals.
• The earned shares will vest on November 30, 2025, contingent upon Morrissey's continued service with Incyte.
• The number of shares ultimately received can range from 0% to 150% of the performance shares awarded, depending on the achievement of the specified goals over a three-year period.
• Following the transaction, Morrissey beneficially owns 86,164 shares, which includes 32,156 shares issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by an executive is generally a positive sign, indicating confidence in the company. However, the vesting is contingent and the ultimate number of shares depends on performance, introducing some uncertainty.

Positives

• The acquisition of shares by an executive demonstrates confidence in the company's performance and future prospects.
• The performance-based nature of the award aligns executive compensation with the achievement of specific company goals, particularly related to Opzelura.
• Continued service requirement for vesting ensures the executive's commitment to the company's success.

Risks

• The vesting of the shares is contingent upon continued service, so Morrissey leaving the company before November 30, 2025, would impact the actual shares received.
• The ultimate number of shares received depends on the achievement of Opzelura performance goals, which introduces uncertainty.

Future Outlook

The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded.

Industry Context

Executive compensation packages often include performance-based equity awards to align management's interests with those of shareholders. The specific performance metrics tied to Opzelura suggest its importance to Incyte's strategy.

Comparison to Industry Standards

• Performance-based equity compensation is a common practice among publicly traded companies, particularly in the pharmaceutical industry.
• Companies like Regeneron and Vertex Pharmaceuticals also utilize performance-based equity awards tied to specific product milestones or financial targets.
• The vesting schedules and performance metrics vary depending on the company and the specific role of the executive.

Stakeholder Impact

• Shareholders: The acquisition of shares by an executive can be viewed positively, signaling confidence in the company's future.
• Employees: Performance-based compensation can incentivize employees to achieve company goals.
• Customers: The focus on Opzelura performance suggests a commitment to the product's success, potentially benefiting patients.

Next Steps

• Continued monitoring of Incyte's performance, particularly related to Opzelura, to assess the ultimate value of the performance shares.
• Observation of Morrissey's continued service with the company through November 30, 2025.

Key Dates

Keywords

Incyte, Morrissey, stock, performance shares, Opzelura, beneficial ownership, vesting, executive compensation